Cancer API companies could be organizations that specialize in developing Application Programming Interfaces (APIs) related to cancer research, diagnosis, treatment, or other aspects of oncology. APIs are sets of protocols and tools for building software applications, and in the context of cancer, these APIs could facilitate the integration of various tools, data sources, or algorithms to enhance the capabilities of healthcare and research applications.
Latest Cancer API Companies Updates:
Biocon Biopharma Ltd. partners with Merck KGaA for an undisclosed multi-year deal: This collaboration announced in October 2023 focuses on developing and manufacturing high-value APIs for oncology drugs.
WuXi AppTec acquires Alvotech Holdings for around $3.3 billion: This acquisition in December 2023 bolsters WuXi's API manufacturing capabilities and expands its oncology portfolio.
Samsung Biologics announces a $300 million investment to expand its API manufacturing capacity: This move in September 2023 aims to meet the growing demand for oncology APIs.
Lonza invests $80 million in its Visp, Switzerland site to expand its API production capacity for highly potent active pharmaceutical ingredients (HPAPIs): This commitment emphasizes the focus on complex APIs for cancer drugs.
Novavax secures FDA approval for its protein-based COVID-19 vaccine, Nuvaxovid: This approval in July 2023 opens doors for future development of similar cancer vaccines.
AstraZeneca announces positive Phase III results for its ADC (Antibody-Drug Conjugate) therapy for lung cancer: This breakthrough in December 2023 could lead to a new targeted treatment option.
List of Cancer API Key companies in the market:
Cancer API Market Highlights:
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)